LION bioscience Launches pathSCOUT(TM) Software for the Analysis and Understanding of Biological Pathways
HEIDELBERG, Germany, June 18 /PRNewswire/ -- LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO, WKN 504 350) today announced the release of pathSCOUT(TM) 1.0, the first commercially available application for the visualization and analysis of biological pathways. pathSCOUT(TM) and piSCOUT(TM), which was also released today, are new modules for LION's integrated Life Science Informatics Platform which is being developed to shorten product development cycles in the Life Science industry. The first three pathSCOUT(TM) systems will be installed at Paradigm Genetics, Nestle and the Japanese Cancer Research Center.
"Assigning proteins to metabolic and signal transduction pathways is a major goal during the process of target identification and validation. We are very pleased to be the first company on the market to offer an advanced pathway analysis software package to our customers," said Dr. Georg Casari, Senior Vice President of Life Science Informatics Research at LION bioscience. "This launch further underlines our strategy of facilitating and accelerating research by developing a network of communicating software modules, each of which addresses a critical process in the product development cycle of life science companies."
pathSCOUT(TM) provides the visualization capabilities and analytical tools for an important class of proteomics data: Biological pathway assignments result from world-wide in-depth scientific investigations, many of which were fueled by the numerous genome sequencing efforts in recent years. Version 1.0 of pathSCOUT(TM) enables researchers to create interactive metabolic pathway graphs on the fly, to integrate proprietary metabolic pathways data with information from the public domain, and to make that combined information available to the entire organization. Furthermore, the application integrates with LION's enterprise software for expression data analysis, arraySCOUT(TM), and with its new software for molecular network analysis, piSCOUT(TM), which was also launched today.
pathSCOUT(TM) 1.0 contains data on metabolic pathways from the well known KEGG* suite of databases which has been optimized by LION for use in the pathSCOUT(TM) system. A graphical representation of signal transduction data is currently under development.
For further information please refer to lionbioscience.com
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION offers these solutions via two primary lines of business:
-- i-biology(R): the installation and implementation of enterprise-wide
horizontal information and knowledge management solutions as part of
LION's Life Science Informatics (LSI(TM)) line of business; and
-- Integrated Drug Discovery and Diagnostics (iD(3)(TM)): application of
i-biology(R) to LION's internal drug discovery program with the goal
to out-license specific databases, polymorphism marker panels, and
validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 440 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.
All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-4 declared effective by the SEC on February 9, 2001. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.
LION bioscience(R) and i-biology(R) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners. Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in the United States. Trega(R) is a registered trademark of Trega Biosciences, Inc.
For further information please contact:
LION bioscience
Dr. Andrea Kreisselmeier
Director Corporate Marketing & Communications
49 (0)6221-4038 265
andrea.kreisselmeier@lionbioscience.com
Noonan/Russo Communications
Matthew Scampoli
1 212-696-4455 ext. 243
m.scampoli@noonanrusso.com
MAKE YOUR OPINION COUNT -- Click Here
tbutton.prnewswire.com
SOURCE Lion bioscience AG
CO: Lion bioscience AG
ST: Germany
IN: MTC BIO STW
SU: PDT
06/18/2001 01:30 EDT prnewswire.com |
